Development of a Novel Graded Prognostic Assessment (BC-LGPA) Model for Breast Cancer Leptomeningeal Metastasis

A Multicenter Cohort Study of Leptomeningeal Metastasis in Breast Cancer: Clinical Characterization and Development of a Novel Graded Prognostic Assessment (BC-LGPA) Model

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07386886

Enrollment

403

Registered

2026-02-04

Start date

2013-11-30

Completion date

2026-01-26

Last updated

2026-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leptomeningeal Metastasis in Breast Cancer

Brief summary

The investigators conducted a large, multicenter retrospective study of patients with breast cancer leptomeningeal metastasis (BCLM), constituting one of the largest and most comprehensively curated cohorts to date. Data from 403 patients diagnosed between November 2013 and November 2025 were collected from three major academic centers. Detailed clinical, pathological, diagnostic, and treatment data were analyzed. Overall survival (OS) was evaluated, and independent prognostic factors were identified via Cox regression. A novel Breast Cancer Leptomeningeal Graded Prognostic Assessment (BC-LGPA) model was developed and validated for risk stratification.

Interventions

DRUGsystematic therapy

Patients with BCLM receive systematic therapy，IT and radiation.

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* patients with BCLM

Exclusion criteria

* patients with other BC CNS metastasis

Design outcomes

Primary

Measure	Time frame	Description
Overall survival	Up to approximately 30 months	Time from date of randomization to the date of death from any cause

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026